IJS - International Journal of Sciences
2023
Fabiano F. Da Silva, Thaysa Adriane Costa Bernardo, Johny Ricarte Das Silva Rodrigues et al.
1 citation
Psilocybin in the treatment of generalized anxiety disorder has become a strong point since it can have important benefits in the treatment. The general objective of the present study is to review the literature on the use of psilocybin in the treatment of generalized anxiety disorder (GAD), alcoholism and smoking, in order to compile and analyze the available evidence on its efficacy, safety...
The Meducator
2023
Alam Mehrjerdi Zahra, Bhavana Soma
2 citations
Psilocybin is a naturally occurring compound present in numerous mushroom species characterised by its hallucinogenic and psychedelic effects. Although it has a negative reputation, psilocybin has demonstrated therapeutic potential for treating mental health disorders by allowing the brain to make new neural connections which help the neural pathways adapt and break out of certain cognitive...
Therapeutic Advances in Psychopharmacology
2023
Ricarda Evens, Tomislav Majić, Timo Torsten Schmidt et al.
49 citations
Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the ‘psychedelic afterglow’, have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period....
Neurosurgery
December 8, 2022
Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi et al.
13 citations
After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and...
International Journal of Surgery Global Health
November 1, 2022
Hamna Raheel, Unaiza Naeem, Asim Shaikh et al.
Mental health disorders such as depression and anxiety are major contributors to the overall global health burden. COVID-19 has further aggravated mental health disorders and also increased substance abuse due to lockdowns1. The Global Burden of Disease reported that the pandemic has led to a 27.6% increase in cases of major depressive disorder (MDD) and a 25.6% increase in cases of anxiety...
Cureus
November 1, 2022
Ricardo Irizarry, Amelia Winczura, Omar Dimassi et al.
26 citations
Psilocybin is an emerging potential therapy for the treatment of psychiatric illnesses. Microdosing has been shown to result in an overall improvement in patients with anxiety, depression, obsessive-compulsive disorder, post-traumatic stress disorder, and substance abuse. This meta-analysis explores and compiles prior research to make further inferences regarding psilocybin and its use for the...
October 26, 2022
George Danias, Jacob Appel
BACKGROUND Psychedelic substances have demonstrated promise in the treatment of depression, anxiety, and substance use disorders. Significant media coverage has been dedicated to psychedelic medicine, but it is unclear whether the public associates psilocybin with its potential therapeutic benefits. The COVID-19 pandemic led to an increase in depression, anxiety, and substance abuse in the...
October 5, 2022
Terence H. W. Ching, Stephen A. Kichuk, Giuliana DePalmer et al.
5 citations
preprint
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, placebo-controlled study), will...
Frontiers in Psychology
October 5, 2022
Anna Søndergaard, Brice Ozenne, Sophia Armand et al.
35 citations
Background Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT 2A R) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in...
Cureus
October 1, 2022
Dev B Goel, Sarju Zilate
24 citations
Psilocybin is a plant alkaloid that is derived from precursors of tryptamine and is present in many different types of mushrooms. It has been utilized by indigenous peoples of Central and South America for centuries in a ceremonial setting to promote spiritual experiences. Indigenous societies have long employed psilocybin and other 5-HT 2A agonist classic psychedelics in their rites. They were...